How Metal Implants Could Mess Up Your Skin
FRIDAY, March 17, 2023 (HealthDay News) — Many patients worry that receiving a metal implant might set off their metal allergy, according to the American Academy of Dermatology.”Cases in which patients are inquiring about a metal allergy as it relate…
Learn MoreFDA Advisors Back Full Approval of Paxlovid
FRIDAY, March 17, 2023 (HealthDay News) — Paxlovid, a medication that has helped millions of high-risk COVID patients avoid hospitalization and death since late 2021, moved one step closer to getting full approval from the U.S. Food and Drug Administ…
Learn MoreDementia Risk Rises for Elite European Soccer Players
FRIDAY, March 17, 2023 (HealthDay News) — It’s well-established that American football players can suffer significant brain impacts as they age.Now, new research shows that elite European soccer players are also more likely than the average person to…
Learn More‘Artificial Pancreas’ Technology Boosts Blood Sugar Control for Young Kids With Type 1 Diabetes
FRIDAY, March 17, 2023 (HealthDay News) — Just like adults, young children with type 1 diabetes may get the blood sugar control they need using an “artificial pancreas,” new research shows. The Control-IQ artificial pancreas system was tested in a cl…
Learn MoreCDC Report Describes Recent Trends in Prevalence of Babesiosis
THURSDAY, March 16, 2023 (HealthDay News) — The prevalence of babesiosis is increasing in certain states, including Maine, New Hampshire, and Vermont, which should now be considered to have endemic transmission, according to research published in th…
Learn MoreMore Emergency Visits for Assault, Self-Harm Reported for Incarcerated Adults
THURSDAY, March 16, 2023 (HealthDay News) — The proportion of emergency department visits resulting from assault and self-harm is higher among incarcerated adults than among nonincarcerated adults, according to research published in the March 17 iss…
Learn MoreLebrikizumab Effective for Adults, Teens With Atopic Dermatitis
THURSDAY, March 16, 2023 (HealthDay News) — For adults and adolescents with moderate-to-severe atopic dermatitis, 16 weeks of lebrikizumab is effective, according to a study published online March 15 in the New England Journal of Medicine.Jonathan I….
Learn More